Investigational Drug Information for Tipifarnib
✉ Email this page to a colleague
What is the development status for investigational drug Tipifarnib?
Tipifarnib is an investigational drug.
There have been 83 clinical trials for Tipifarnib.
The most recent clinical trial was a Phase 3 trial, which was initiated on November 1st 1999.
The most common disease conditions in clinical trials are Leukemia, Leukemia, Myeloid, and Leukemia, Myeloid, Acute. The leading clinical trial sponsors are National Cancer Institute (NCI), Kura Oncology, Inc., and Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Summary for Tipifarnib
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 3,131 |
| WIPO Patent Applications | 2,159 |
| Japanese Patent Applications | 2 |
| Clinical Trial Progress | Phase 3 (1999-11-01) |
| Vendors | 66 |
Recent Clinical Trials for Tipifarnib
| Title | Sponsor | Phase |
|---|---|---|
| Combination Trial of Tipifarnib and Alpelisib in Adult Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) | Kura Oncology, Inc. | Phase 1/Phase 2 |
| A Phase I, Single Center, Open-label Clinical Pharmacology Study to Evaluate the Effect of Tipifarnib on Cardiac Safety in Subjects With Advanced Solid Malignancies | Kura Oncology, Inc. | Phase 1 |
| Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial | National Cancer Institute (NCI) | Phase 2 |
Clinical Trial Summary for Tipifarnib
Top disease conditions for Tipifarnib
Top clinical trial sponsors for Tipifarnib
US Patents for Tipifarnib
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
